Publication:
A strategic reflection for the management and implementation of CAR-T therapy in Spain: an expert consensus paper.

dc.contributor.authorZozaya, N
dc.contributor.authorVillaseca, J
dc.contributor.authorAbdalla, F
dc.contributor.authorCalleja, M A
dc.contributor.authorDíez-Martín, J L
dc.contributor.authorEstévez, J
dc.contributor.authorGarcía-Sanz, R
dc.contributor.authorMartínez-López, J
dc.contributor.authorSierra, J
dc.contributor.authorVera, R
dc.contributor.authorHidalgo-Vega, A
dc.date.accessioned2023-05-03T13:54:57Z
dc.date.available2023-05-03T13:54:57Z
dc.date.issued2022-01-08
dc.description.abstractCAR-T cell therapy represents a therapeutic revolution in the prognosis and treatment of patients with certain types of hematological cancer. However, they also pose new challenges in the healthcare, regulatory and financial fields. The aim of the RET-A project was to undertake a strategic reflection on the management of CAR-T therapies within the Spanish National Health System, to agree on recommendations that will help to better deal with the new context introduced by these cell therapies in the present and in the future. This think tank involved 40 key agents and opinion leaders. The experts identified three great challenges for implementing advanced therapies in Spain: therapeutic individualisation, with a multidisciplinary approach; acceleration of access times, by minimizing bureaucracy; and increase in the number of centers qualified to manage the CAR-T therapies in the NHS. The experts agreed on the ideal criteria for designating those qualified centers. They also agreed on a comprehensive CAR-T care pathway with the timings and roles which would ideally be involved in each part of the process.
dc.identifier.doi10.1007/s12094-021-02757-9
dc.identifier.essn1699-3055
dc.identifier.pmcPMC8741571
dc.identifier.pmid34997475
dc.identifier.pubmedURLhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8741571/pdf
dc.identifier.unpaywallURLhttps://link.springer.com/content/pdf/10.1007/s12094-021-02757-9.pdf
dc.identifier.urihttp://hdl.handle.net/10668/21008
dc.issue.number6
dc.journal.titleClinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico
dc.journal.titleabbreviationClin Transl Oncol
dc.language.isoen
dc.organizationHospital Universitario Virgen Macarena
dc.organizationHospital Universitario Virgen Macarena
dc.page.number968-980
dc.pubmedtypeJournal Article
dc.pubmedtypeReview
dc.rightsAttribution 4.0 International
dc.rights.accessRightsopen access
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/
dc.subjectAdvanced therapies
dc.subjectCAR-T therapy
dc.subjectNational health system
dc.subjectSpain
dc.subject.meshConsensus
dc.subject.meshHematologic Neoplasms
dc.subject.meshHumans
dc.subject.meshImmunotherapy, Adoptive
dc.subject.meshReceptors, Chimeric Antigen
dc.subject.meshSpain
dc.titleA strategic reflection for the management and implementation of CAR-T therapy in Spain: an expert consensus paper.
dc.typeresearch article
dc.type.hasVersionVoR
dc.volume.number24
dspace.entity.typePublication

Files

Original bundle

Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
PMC8741571.pdf
Size:
1.1 MB
Format:
Adobe Portable Document Format